Novartis Revenue Growth Hits 8% Despite Entresto and Promacta Generic Erosion
Novartis AG (NYSE: NVS) reported full‑year 2025 net sales of USD 54.5 billion, up 8% year‑on‑year (YOY) at...
Novartis AG (NYSE: NVS) reported full‑year 2025 net sales of USD 54.5 billion, up 8% year‑on‑year (YOY) at...
Pfizer Inc. (NYSE: PFE) reported full‑year 2025 revenue of USD 62.6 billion, representing a 2% operational decline at constant...
Merck & Co. (MSD, NYSE: MRK) reported full‑year 2025 revenue of USD 65.5 billion, up 2% year‑on‑year...
Beijing Aosaikang Pharmaceutical Co., Ltd. (SHE: 002755) announced that China’s National Medical Products Administration (NMPA)...
China’s Center for Drug Evaluation (CDE) announced it is seeking public feedback on the 101st...
Tibet Weixikang Pharmaceutical Co., Ltd. (SHA: 603676) announced that its lidocaine-tetracaine cream has received approval...
Zhejiang Jiuzhou Pharmaceutical Co., Ltd. (SHA: 603456) announced that its Abbreviated New Drug Application (ANDA)...
The National Health Commission (NHC) today released its fourth catalogue of medicines earmarked for generic...
Guangdong Taienkang Pharmaceutical Co., Ltd. (SHE: 301263) announced that the National Medical Products Administration (NMPA)...
Sino Biopharmaceutical Limited (HKG: 1177) announced that its subsidiary Jiangsu Chia Tai Tianqing Pharmaceutical Co.,...
China‑listed Kexing Biopharm Co., Ltd. (SHA: 688136) announced today a strategic commercialization agreement with Humanwell...
China-based Yifan Pharmaceutical Co., Ltd (SHE: 002019) announced that the National Medical Products Administration (NMPA)...
China-based Zhejiang Huahai Pharmaceutical Co., Ltd (SHA: 600521) announced that it has received a warning...
China’s Harbin Pharmaceutical Group Holding Co., Ltd (SHA: 600664) announced a technology transfer agreement with...
China-based Humanwell Healthcare (Group) Co., Ltd (SHA: 600079) announced that it has received clinical trial...
China-based Hainan Shuangcheng Pharmaceutical Co., Ltd (SHE: 002693) announced that the market filing for its...
China-based Hefei Lifeon Pharmaceutical Co., Ltd (SHE: 003020) announced that it has received clinical trial...
The US Department of Commerce (DoC) has initiated a Section 232 investigation to evaluate the...
China’s Beijing Aosaikang Pharmaceutical Co., Ltd (SHE: 002755) has revealed that a market filing for...
Chengdu-based Easton Pharmaceutical Co., Ltd (SHA: 688513) has announced that it has received separate marketing...